Skip to content
Medical Health Aged Care

Funding cut for GP ECG services a ticking time bomb

Royal Australian College of GPs 2 mins read

Over 2.2 million heart health tests were not delivered by GPs due to Federal Government funding cuts in 2020, creating a ticking time bomb for millions of Australians, Royal Australian College of GPs President Dr Nicole Higgins is warning.   

Australia’s peak GP body, the RACGP, has called for revised Medicare Benefits Schedule (MBS) items to be introduced without delay in its submission to a review of changes to ECG MBS items.  

RACGP President Dr Nicole Higgins said: “Funding needs to be restored immediately for Australians to get this care from their GP – it’s been almost four years since the Federal Government cut this funding, and the risk of people with life threatening problems being missed since then is huge.   

“The RACGP strongly opposed the funding cut which restricted certain ECG services to non-GP specialists and consultant physicians, which costs patients much more. 

“As a result of this funding cut, 2.2 million fewer ECG services were provided to patients from 2020 to 2022. 

“Coronary heart disease is the leading cause of death in Australia. Timely diagnosis and management of heart conditions is key to saving lives. 

“We’ll never know how many patients with heart issues have missed out, who’s health has got worse, and the lives lost that we could have saved in the four years since this funding was cut. 

“We do know people in rural and remote communities have been hardest hit because local cardiologists are rare. So, when the government cut funding for Australians to get this care from their GP, it cut many people in rural communities off entirely unless they make a long drive or fly to their nearest specialist.   

“It may have saved the government’s bottom line in the short term, but it’s risking the health of Australians across the country every day. 

“Preventive heart disease screening via ECGs in general practice could prevent over 67,000 heart attacks, strokes, and deaths over five years, according to the Heart Foundation. 

“Other specialists also rely on the expertise of GPs to perform and interpret ECGs, such as before a patient starts stimulant medicines for ADHD treatment, so it’s impacting access to care in many other ways.   

“In the current cost-of-living crisis it’s critical that this funding is returned without delay. This is about restoring access to care for Australians, reducing costs, and ultimately saving lives.” 

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 17/09/2024
  • 22:56
Ripple Therapeutics

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.Ripple's patented technology platform is based on…

  • Medical Health Aged Care
  • 17/09/2024
  • 15:11
Galderma

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/09/2024
  • 08:40
UNSW Sydney

New electricity-free soft robot could aid precise surgery

Biomedical engineers have developed a new soft robotic system that works without electricity or motors, allowing for more precise surgeries at lower cost. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.